Tirofiban

Drugs of Today

Volumn 35, Issue 1, 1999, Pages 59-73

  Théroux, Pierre ^a  

^a MONTREAL HEART INSTITUTE   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; ENOXAPARIN; FIBRINOGEN RECEPTOR; HEPARIN; LOW MOLECULAR WEIGHT HEPARIN; TIROFIBAN;

BLEEDING TIME; DOSE RESPONSE; DRUG EFFICACY; DRUG ELIMINATION; DRUG SAFETY; HEART INFARCTION; HEART MUSCLE ISCHEMIA; HUMAN; REVIEW; RISK BENEFIT ANALYSIS; THROMBOCYTE AGGREGATION INHIBITION; THROMBUS; TRANSLUMINAL CORONARY ANGIOPLASTY; UNSTABLE ANGINA PECTORIS;

EID: 0344061512     PISSN: 16993993     EISSN: 16994019     Source Type: Journal    
DOI: 10.1358/dot.1999.35.1.522949     Document Type: Review

References (29)

1. Theroux, P., Fuster, V. Acute coronary syndromes: Unstable angina and non-Q-wave myocardial infarction. Circulation 1998, 97: 1195-206.
2. Fuster, V., Badimon, L., Cohen, M. et al Insights into the pathogenesis of acute ischemic syndromes. Circulation 1988, 77: 1213-20.
3. Plow, E.F., Ginsberg, M.H. Cellular adhesion: GPIIb/IIIa as a prototypic adhesion molecule. Prog Hemost Thromb 1988, 296: 320-31.
4. Coller, B.S. Blockade of platelet GPIIb/IIIa receptors as an antithrombotic strategy. Circulation 1995, 92: 2373-80.
5. Hartman, G.D., Egbertson, M.S., Halczenko W. et al. Non-peptidic fibrinogen receptor antagonists: 1. Discovery and design of exosite inhibitors. J Med Chem 1992, 36: 4640-2.
6. Merck & Co., Inc. Tirofiban hydrochloride: Worldwide clinical summary. West Point, PA 1997.
7. Umemura, K. Kondo, K. Ikeda, Y., Nakashima, M. Enhancement by ticlopidine of the inhibitory effect on in vitro platelet aggregation of the glycoprotein IIb/IIIa inhibitor tirofiban. Thromb Haemost 1997, 78: 1381-4.
8. Barrett, J.S., Murphy, G., Peerlinck, K., et al. Pharmacokinetics and pharmacodynamics of MK-383, a selective non-peptide platelet glycoprotein-IIb/IIIa receptor antagonist, in healthy men. Clin Pharmacol Ther 1994, 56: 377-88.
9. Théroux, P., White, H., David, D. et al. Pilot dose ranging studies of tirofiban in patients with unstable angina. J Am Coll Cardiol 1998, submitted.
10. Merck & Co., Inc. Aggrastat® (tirofiban hydrochloride) prescribing information. West Point, PA 1998.
11. Klein, W., Buchwald, A., Hillis, S.E. et al. Comparison of low-molecular-weight heparin with unfractionated heparin acutely and with placebo for 6 weeks in the management of unstable coronary artery disease - Fragmin in Unstable Coronary Artery Disease Study (FRIC). Circulation 1997, 96: 61-8.
12. Cohen, M., Demers, C., Gurfinkel, E.P. et al. A comparison of low-molecular-weight heparin with unfractionated heparin for unstable coronary artery disease. Efficacy and Safety of Subcutaneous Enoxaparin in Non-Q-Wave Coronary Events Study Group. New Engl J Med 1997, 337:447-52.
13. Gould, R.J., Chang, C.T.C., Lynch, R.J. et al. MK-0383 is a potent non-peptide mimic of RGD that inhibits glycoprotein IIb/IIIa. Thromb Haemost 1993, 69: 976.
14. Lynch, J.J. Jr., Cook, J.J., Sitko, G.R. et al. Nonpeptide glycoprotein IIb/IIIa inhibitors. 5. Antithrombotic effects of MK-0383. J Pharmacol Exp Ther 1995, 272: 20-32.
15. Peerlink, K., de Lapeleire, l., Goldberg, M. et al. MK-383 (L-700,462), a selective nonpeptide platelet glycoprotein IIb/IIIa antagonist, is active in man. Circulation 1993, 88: 1512-7.
16. Kereiakes, D.J., Kleiman, N.S., Ambrose, J. et al. Randomized, double-blind, placebo-controlled, dose-ranging study of tirofiban (MK-383) platelet IIb/IIIa blockade in high risk patients undergoing coronary angioplasty. J Am Coll Cardiol 1996, 27: 536-42.
17. Hiramatsu, Y., Gikakis, N., Anderson, H.L. III. et al. Tirofiban provides "platelet anaesthesia" during cardiopulmonary bypass in baboons. J Thorac Cardiovasc Surg 1997, 113: 182-93.
18. The Platelet Receptor Inhibition in Ischemic Syndrome Management (PRISM) Study Investigators. A comparison of aspirin plus tirofiban with aspirin plus heparin for unstable angina. New Engl J Med 1998, 338: 1498-505.
19. The Platelet Receptor Inhibition in Ischemic Syndrome Management in Patients Limited by Unstable Signs and Symptoms (PRISM-PLUS) Study Investigators. Inhibition of the platelet glycoprotein IIb/IIIa receptor with tirofiban in unstable angina and non-Q-wave myocardial infarction. New Engl J Med 1998, 338: 1488-97.
20. The RESTORE Investigators. Effects of platelet glycoprotein IIb/IIIa blockade with tirofiban on adverse cardiac events in patients with unstable angina or acute myocardial infarction undergoing coronary angioplasty. Circulation 1997, 96: 1445-53.
21. Oler, A., Whooley, M.A., Oler, J., Grady, D. Adding heparin to aspirin reduces the incidence of myocardial infarction and death in patients with unstable angina. JAMA 1996, 276: 811-5.
22. Hass, W.K., Easton, J.D., Adams, H.P. Jr. et al. A randomized trial comparing ticlopidine hydrochloride with aspirin for the prevention of stroke in high-risk patients. New Engl J Med 1989, 321: 501-7.
23. CAPRIE Steering Committee. A randomized, blinded trial of clopidogrel versus aspirin in patients at risk of ischemic events (CAPRIE). Lancet 1996, 348: 1329-38.
24. The EPIC Investigators. Use of a monoclonal antibody directed against the platelet glycoprotein IIb/IIIa receptor in high-risk coronary angioplasty. New Engl J Med 1994, 330: 956-61.
25. The EPILOG Investigators. Platelet glycoprotein IIb/IIIa receptor blockade and low-dose heparin during percutaneous coronary revascularization. New Engl J Med 1997, 336: 1689-96.
26. The CAPTURE Investigators. Randomized placebo-controlled trial of abciximab before and during coronary intervention in refractory unstable angina: The CAPTURE study. Lancet 1997, 349: 1429-35.
27. The EPISTENT Investigators. Randomized placebo-controlled trial and balloon-angioplasty controlled trial to assess safety of coronary stenting with use of platelet glycoprotein IIb/IIIa blockade. Lancet 1998, 352: 87-92.
28. The IMPACT-II Investigators. Randomized placebo-controlled trial of effect of eptifibatide on complications of percutaneous coronary intervention: IMPACT II. Lancet 1997, 349: 1422-8.
29. The PURSUIT Investigators. A randomized comparison of the platelet glycoprotein IIb/IIIa peptide inhibitor eptifibatide with placebo in patients without persistent ST-segment elevation acute coronary syndromes. New Engl J Med 1998, 339: 436-43.